Verdict No. 3066 · Search date 2026-09-08 · Methodology v1.0
Aged garlic extract 2.4-7.2 g/day,
does it really help with Reduction of ex vivo platelet aggregation?
30-Second Summary
C
Evidence Grade C · 46 · Safety warning
Only agonist-specific ex vivo aggregation is judged; clinical thrombosis and bleeding time are separate.
Warning. Because platelet effects are possible, do not self-administer with anticoagulants, antiplatelets, bleeding disorders, or around surgery.
What the
research showsGrade C with 46 points. A 34-person dose study reduced some collagen- and epinephrine-induced aggregation, with only a weak highest-dose ADP signal, while another placebo trial found no reduction with ADP, PAF, or collagen. A review of 12 RCTs could not reach a firm conclusion.
research showsGrade C with 46 points. A 34-person dose study reduced some collagen- and epinephrine-induced aggregation, with only a weak highest-dose ADP signal, while another placebo trial found no reduction with ADP, PAF, or collagen. A review of 12 RCTs could not reach a firm conclusion.
What the
ads claimThis cannot become a claim of thrombosis prevention, thrombolysis, aspirin replacement, or bleeding safety.
ads claimThis cannot become a claim of thrombosis prevention, thrombolysis, aspirin replacement, or bleeding safety.
Useful facts when choosing a product
- This verdict applies only to the displayed formulation, route, dose, duration, population, endpoint, and comparator.
- Raw garlic, powder, garlic oil, stabilized-allicin products, aged garlic extract, black garlic, fermented garlic, and isolated S-allylcysteine are not interchangeable.
- Warning. Because platelet effects are possible, do not self-administer with anticoagulants, antiplatelets, bleeding disorders, or around surgery.
Chamgap Semantic Classification Code
Permanent code issued
S.aged-garlic-extract.oral.platelet-aggregation.reduce.placeboSupplements and nutraceuticals > Aged garlic extract > Oral > Ex vivo platelet aggregation > Reduction claim > Placebo
Bound to agonist-specific ex vivo platelet aggregation; clinical thrombosis, bleeding time, and drug substitution are separate. The code identifies the intervention and claim; it never contains the evidence grade, score, or safety result.
Exact Claim Classification
These independent facets prevent evidence from different forms, routes, populations, effects, and comparators from being mixed.
| Intervention class | S · Supplement or nutraceutical |
|---|---|
| Canonical ingredient or intervention | Aged garlic extract |
| Source or part used | Aged extract of Allium sativum L. cloves |
| Formulation or processing | AGE capsules; trial-specific SAC specification unverified |
| Route | Oral |
| Dose | 2.4, 4.8, or 7.2 g/day in the dose-ranging trial |
| Duration | Short term; duration varied by trial |
| Population | Primarily healthy adults; concomitant antiplatelet therapy is separate |
| Effect or condition | Reduced platelet aggregation |
| Primary endpoint | Ex vivo maximum aggregation or threshold to a prespecified agonist |
| Comparator | Placebo |
| Duplicate-detection key | Aged garlic extract|AGE capsules; trial-specific SAC specification unverified|Oral|Primarily healthy adults; concomitant antiplatelet therapy is separate|Reduced platelet aggregation|Short term; duration varied by trial |
Gap Measurement · Verdict 3066 · C 46
What the research actually shows
A 2022 review of 12 RCTs, a 34-person AGE dose study, and an independent null trial were separated by agonist.
Why this is classified as C (46)
There are no counted strengths; R0, EX, small short trials, and multiplicity yield C/46.
Counterpoint. Some high-dose signals support biological plausibility, but independent placebo null results and heterogeneity remain.
Rejudgment record. Independent Codex cross-check — One formulation, route, population, claim, principal endpoint, and comparator
Scoring profile behind this grade
| Endpoint | S | Surrogate marker - laboratory or imaging measures |
| Replication | R0 | Trials conflict in direction |
| Independence | I1 | Mixed funding sources |
| Effect size | EX | The clinical size of the effect could not be judged |
| Precision | CX | No pooled confidence interval could be confirmed |
The scoring table and the verdict agree (C).
Cross-check — AI research and Codex final gate
AI was used for research and drafting. Blind grading, adversarial audit, and the methodology boundary rules were then reapplied before Codex performed the final evidence, grade, copy, and build checks. If a grade cannot be narrowed, both evidence positions and their reasons are published.
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| The effects of aged garlic extract on platelet aggregation and adhesion in humans | The cited design, allocation, masking, endpoint hierarchy, and analysis limitations were independently checked. | 34 | Funding, product support, employee authorship, and declared conflicts were assessed separately. | The principal endpoint contract is preserved; secondary outcomes remain separate. | Verified estimates are preserved; missing confidence intervals or event counts were not invented. | Evidence weight reflects directness, formulation match, endpoint hierarchy, and reporting limitations. |
| Effect of a garlic preparation on in vitro platelet aggregation in healthy subjects | The cited design, allocation, masking, endpoint hierarchy, and analysis limitations were independently checked. | Funding, product support, employee authorship, and declared conflicts were assessed separately. | The principal endpoint contract is preserved; secondary outcomes remain separate. | Verified estimates are preserved; missing confidence intervals or event counts were not invented. | Evidence weight reflects directness, formulation match, endpoint hierarchy, and reporting limitations. | |
| Garlic supplementation and platelet aggregation: a systematic review of randomized controlled trials | The cited design, allocation, masking, endpoint hierarchy, and analysis limitations were independently checked. | 595 | Funding, product support, employee authorship, and declared conflicts were assessed separately. | The principal endpoint contract is preserved; secondary outcomes remain separate. | Verified estimates are preserved; missing confidence intervals or event counts were not invented. | Evidence weight reflects directness, formulation match, endpoint hierarchy, and reporting limitations. |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-09-08).
Steiner M, Li W. J Nutr. 2001;131:980S-984S. PMID: 11238801. DOI: 10.1093/jn/131.3.980S.
checkedResearch and draft: AI used · Cross-check: blind grading and adversarial audit
Final verification and publication gate: Codex · Verification cutoff: 2026-09-08 · Corrections: none
Final verification and publication gate: Codex · Verification cutoff: 2026-09-08 · Corrections: none
Cite this verdict
[Chamgap] Aged Garlic Extract for Platelet Aggregation—Small Trials Disagreed Across Agonists — Evidence Grade C·46. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/heart/aged-garlic-extract-ex-vivo-platelet-aggregation/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.